.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Management of Myeloproliferative Neoplasms

EP. 1: An Overview of Myeloproliferative Neoplasms

July 10th 2018

EP. 2: MPNs: Differentiating Between ET, PV, and MF

July 10th 2018

EP. 3: Suspecting Polycythemia Vera: Challenges in Diagnosis

July 10th 2018

EP. 4: Polycythemia Vera: Making a Diagnosis

July 10th 2018

EP. 5: Polycythemia Vera: Considerations for Frontline Therapy

July 10th 2018

EP. 6: Determining Inadequate Control or Intolerance in PV

July 10th 2018

EP. 7: Polycythemia Vera: Controlling HCT and WBC

July 10th 2018

EP. 8: Selecting Appropriate Therapy at Progression of PV

July 10th 2018

EP. 9: Ruxolitinib's Role in Treating Polycythemia Vera

July 10th 2018

EP. 10: Optimizing the Use of Ruxolitinib for Polycythemia Vera

July 10th 2018

EP. 11: Myelofibrosis: Diagnosis and Risk Stratification

July 10th 2018

EP. 12: Ruxolitinib's Role in Treating Myelofibrosis

July 10th 2018

EP. 13: Polycythemia Vera: Novel JAK Inhibitors

July 10th 2018

EP. 14: Treating Anemia With Luspatercept in MDS

July 10th 2018

EP. 15: Determining the Potential of Ropeginterferon Alfa-2b in Polycythemia Vera

July 10th 2018

EP. 16: Unmet Needs and Future Directions in Treating MPNs

July 10th 2018